Natera (NTRA) Stock News

Natera's Signatera test will identify MRD-positive patients for TransCode's Phase 2a trial of TTX-MC138 in colorectal cancer, targeting an unmet need in patients with no radiographic evidence of disease.

Natera chairman Rabinowitz gifts 6,000 shares.

Natera's MCED blood assay received FDA Breakthrough Device designation, based on data from 12 cancer types. The designation aims to speed development and review. Natera plans to work with FDA to detect cancer earlier.

Natera announced enrollment of first patients in a randomized trial using its Signatera test to guide treatment escalation in advanced melanoma. The study, sponsored by NYU Langone, aims to detect molecular residual disease earlier to intensify therapy before radiographic progression.

Natera (NTRA) presented four oral abstracts at ASTRO 2026, its first participation at the radiation oncology conference. Signatera demonstrated high sensitivity and specificity for recurrence detection in locally advanced rectal cancer, identified high-risk groups in anal cancer, and showed utility in vulvovaginal and cervical cancers. The data supports Signatera's role in treatment response monitoring and risk stratification for radiation oncologists.

Natera Q2 Revenue Beats Estimates, lifts Full-Year Guidance.